Skip to content

Summit Therapeutics SMMT Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax

Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax at other companies

Allegion logo
AllegionALLE
$525K+291%
Aptiv logo
AptivAPTV
-$283M-261%
Acuity Brands logo
Acuity BrandsAYI
-$4.75M-439%
Kimberly-Clark logo
Kimberly-ClarkKMB
-$35.25M-205%
ATI logo
ATIATI
$9.78M+183%
Arch Capital Group logo
Arch Capital GroupACGL
-$1.53M-333%

Other financials

Income statement

See full
Revenue-
Operating income-$65.6M-81.2%
Net income-$189.4M-201%
EPS (diluted)-$0.24-167%

Balance sheet

See full
Cash & equivalents$8.2M+7.2%
Total debt$20.0M+211%
Total equity$545.9M+58.5%
Total assets$647.9M+68.8%

Cash flow

See full
Operating cash flow-$122.3M-99.9%
CapEx$245.0K-41.9%
Free cash flow-$122.5M-99.0%

Valuation

See full
Market cap$10.67B+3.3%
Enterprise value$10.68B+3.4%

Profitability

See full
Operating margin-268,266.8%-272,316pp
Net margin-271,685%-275,966pp
FCF margin-5,931.6%+4,730pp

Returns & leverage

See full
Return on equity-271%-1,725pp
Debt / equity0.0×
Current ratio7.4×-3.2×

Where this comes from

Reported directly by Summit Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax.

The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Summit Therapeutics's other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Summit Therapeutics's other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax?
Summit Therapeutics (SMMT) reported other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax of $84K in Q1 2026.
How has Summit Therapeutics's other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax changed year-over-year?
Summit Therapeutics's other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax increased by 157.9% year-over-year, from -$145K to $84K.
What is the long-term trend for Summit Therapeutics's other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax?
Over 3 years (2022 to 2025), Summit Therapeutics's other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax has grown at a 2.5% compound annual growth rate (CAGR), from $304K to -$327K.
What does other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax mean?
The change in value of foreign operations caused by shifts in currency exchange rates.
How do you interpret other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax?
An increase represents a favorable currency translation gain, while a decrease indicates a negative impact from foreign exchange volatility.
How does other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax compare across companies?
Common for multinational corporations; peers with significant international exposure will show higher volatility in this metric.